Core Insights - Cognition Therapeutics, Inc. has developed a novel chemical process for manufacturing zervimesine (CT1812), enhancing its stability at room temperature and supporting future clinical studies and potential commercial manufacturing [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders, particularly targeting Alzheimer's disease and dementia with Lewy bodies [4] - The company is currently investigating zervimesine (CT1812) in clinical programs, including the ongoing START study for early Alzheimer's disease [4] Product Information - Zervimesine (CT1812) is an investigational oral medication designed to treat central nervous system diseases, specifically targeting the toxic effects of amyloid beta (Aβ) and ɑ-synuclein proteins that damage neurons [3] - The new manufacturing process utilizes innovative technologies such as high throughput screening and light-induced continuous flow processing, which improves the efficiency and safety of zervimesine synthesis [2]
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812)